Swiss pharmaceutical giant Roche is joining a new surge of corporate reshoring with a $50 billion commitment to expand U.S. manufacturing, driven by new White House tariffs and policy incentives.
The investment includes major upgrades in Indiana, Pennsylvania, Massachusetts, and California, along with a 900,000-square-foot facility for next-generation weight-loss drugs at a yet-to-be-disclosed location.
Similar announcements include TSMC’s $100 billion investment in advanced chip plants in Arizona, Eli Lilly’s doubling of its U.S. footprint with four new pharmaceutical sites, and Apple pledging $500 billion toward AI-driven manufacturing and training, including a Houston facility.
Nvidia is launching domestic production of its AI supercomputers in Texas, while Hyundai plans to invest $21 billion to expand its U.S. auto output and innovation efforts.